Aptar: iPUMP® Boosts Adherence to SLIT Allergy Treatment
Aptar Digital Health, a leader in digital health solutions, is pleased to announce the positive results from the SPEED1 survey, which demonstrate the effectiveness of the iPUMP® connected assistant in enhancing patient adherence to Stallergenes Greer’s sublingual liquid immunotherapy (SLIT). These results will be presented by Stallergenes Greer at the upcoming CFA Congress (Congrès Francophone d’Allergologie) in Paris, France, from April 15 to 18, 2025.
The SPEED survey revealed significant improvements in treatment adherence for patients using iPUMP®, with an increase of 15% in adherence rates. Additionally, the survey showed notable benefits for younger patients. Among children aged 5 to 12, parental involvement in administering treatments dropped from 50% to 28% over a three-month period. Meanwhile, the proportion of children independently taking their medication nearly doubled, rising from 24% to 58%. Furthermore, 90% of parents expressed greater confidence with the connected assistant, with half feeling completely at ease with treatment administration. This contrasts with only 36% of parents in the non-iPUMP® group expressing the same level of comfort.
Developed in collaboration with Stallergenes Greer, iPUMP® is designed to support patients in adhering to personalized SLIT treatments. It ensures patients follow the prescribed dosing technique, duration, and frequency of treatment. The device is connected to a companion mobile application, which provides patients with direct access to their individualized treatment protocol, as prescribed by their healthcare provider. Since its launch in February 2023, iPUMP® has been utilized by over 9,000 patients in France. The device not only helps improve adherence but also offers a history-tracking feature, allowing for precise monitoring of medication use.
Elena Rizova, Chief Medical Officer at Stallergenes Greer, commented on the survey findings, saying, “The SPEED survey highlights the positive impact that connected health solutions like iPUMP® have on improving both treatment adherence and patient confidence. These factors are essential to achieving successful therapeutic outcomes.” She continued, “Innovation is at the core of what we do, and iPUMP® was developed in response to the needs of patients and healthcare professionals. By enhancing treatment management, iPUMP® is helping to improve overall allergy care.”
Marcus Bates, VP of Business Development & Global Head of Respiratory at Aptar Digital Health, also praised the results of the SPEED survey, stating, “The strong outcomes from this survey pave the way for the broader adoption of digital and connected solutions in allergy management. With iPUMP®, more patients will have access to an easy-to-use, reliable tool that helps track treatment adherence and stay engaged in their care, leading to better health outcomes.”
iPUMP® is an important addition to the growing field of digital health tools, designed to make chronic disease management more accessible and effective. Its success in the SPEED survey underlines its potential to significantly improve adherence to SLIT, a treatment for patients with allergic rhinitis and other allergy-related conditions. By facilitating consistent and accurate treatment, iPUMP® contributes to optimizing the effectiveness of immunotherapy and enhances the overall patient experience.
Aptar Digital Health’s collaboration with Stallergenes Greer represents a significant milestone in the use of connected solutions for allergy management. By supporting Stallergenes Greer’s mission to empower patients and improve treatment outcomes, Aptar Digital Health solidifies its position as a trusted partner in the development of digital health solutions.
The results of the SPEED survey establish a strong foundation for the wider adoption of iPUMP® and support Stallergenes Greer’s commitment to continuous innovation. As the global demand for digital health solutions grows, iPUMP® offers a promising future for patients, caregivers, and healthcare providers alike, contributing to more effective allergy treatments and improved quality of life.
About Aptar Digital Health
Aptar Digital Health is part of AptarGroup, Inc., a global leader in drug and consumer product dosing, dispensing, and protection technologies. The division creates end-to-end solutions that enhance patient experiences through a holistic ecosystem of digital interventions. Aptar Digital Health’s offerings include mobile and web apps, Software-as-a-Medical-Device (SaMD), connected drug delivery systems, advanced data analytics services, and patient onboarding and training solutions. Aptar’s mission is to empower patients and optimize their treatment journey. With more than 13,000 employees across 20 countries, Aptar is headquartered in Crystal Lake, Illinois.
